HKEX to cut startup IPO threshold, allow confidential filings

Hong Kong Exchanges and Clearing will allow startups to submit IPO applications confidentially and lower the minimum market capitalization threshold for listing, the South China Morning Post reported, citing people familiar with the matter.

The reforms target technology and biotechnology startups that have struggled to meet HKEX's existing listing requirements, the report said. Confidential filings let companies keep financial details private until closer to the listing date, reducing the risk and cost of withdrawing a public application.

The changes come as Hong Kong's IPO market regains momentum. Zhongji Innolight, a Chinese optical module maker, filed confidentially in April and cleared its HKEX hearing on July 17, with plans to raise as much as $8 billion in what would be the city's largest IPO of 2026, surpassing Luxshare Precision's $3.1 billion deal earlier this month. The company is advised by Goldman Sachs, Morgan Stanley, CICC and GF Securities.

The exact new market capitalization threshold has not been disclosed. The current regime requires companies seeking a Main Board listing to meet minimum market cap requirements that vary by sector and revenue level, with the standard threshold set at HK$500 million for profitable companies.

The reforms represent HKEX's latest effort to defend its position as a global listing destination amid intensifying competition from exchanges in Singapore, the US and mainland China. The exchange has also seen a wave of A+H share listings this year, where companies already listed on mainland exchanges seek secondary listings in Hong Kong to access international capital.

The policy shift aligns with Hong Kong's broader push to position itself as a hub for innovation and technology financing. The confidential filing mechanism brings HKEX closer to practices at the Nasdaq and NYSE, where pre-IPO confidentiality is standard.

The lower barriers could accelerate the pipeline of IPOs in the second half of 2026, particularly for AI and biotech startups that previously found the threshold too high. Investors will watch for the first batch of companies to test the new rules, with several Chinese technology firms reportedly evaluating Hong Kong listings.

This article is for informational purposes only and does not constitute investment advice.